EICHORCondition: Advanced Solid Tumor · Sponsor: LaNova Medicines Limited
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
This description comes directly from the study's public registry record.
Alex Yuan · +8615901815211 · alexyuan@lanovamed.com
Paul Kong · +8613564682439 · paulkong@lanovamed.com
Always discuss trial participation with your own doctor first.
| University of Southern California (USC) - Norris Comprehensive Cancer Center | Los Angeles, California, United States | Not Yet Recruiting |
| Ocala Oncology | Ocala, Florida, United States | Recruiting |
| Indiana University Melvan and Bren Simon Cancer Center | Indianapolis, Indiana, United States | Not Yet Recruiting |
| The Christ Hospital | Cincinnati, Ohio, United States | Not Yet Recruiting |
| Mary Crowley Cancer Research Center | Dallas, Texas, United States | Not Yet Recruiting |
| Virginia Cancer Specialists, P.C. | Fairfax, Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06187402